Amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on How Tafamidis is Absorbed in the Blood of Healthy Adults with Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-how-tafamidis-is-absorbed-in-the-blood-of-healthy-adults-with-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 15:05:31 +0000 https://clinicaltrials.eu/trial/study-on-how-tafamidis-is-absorbed-in-the-blood-of-healthy-adults-with-transthyretin-amyloid-cardiomyopathy/ This clinical trial is focused on studying how different forms of the study medicine, tafamidis, are absorbed into the blood in healthy adults. Tafamidis is a medication used to treat a heart condition known as transthyretin amyloid cardiomyopathy, which affects the heart’s ability to function properly. The study will compare the absorption of two different tablet forms of tafamidis (61 mg and 70 mg) to a capsule form (61 mg) when taken by healthy participants who have not eaten.

The purpose of the study is to estimate how well the body absorbs these different forms of tafamidis. Participants will receive a single dose of each form of the medication in a randomized order, meaning the order in which they receive the tablets and capsule will be determined by chance. The study will take place over three periods, with each participant receiving all three forms of the medication at different times. This approach helps researchers understand the differences in how the body takes up each form of the medication.

Throughout the study, participants will be monitored to measure the levels of tafamidis in their blood. This information will help determine the relative bioavailability, which is a term used to describe how much of the drug enters the bloodstream and is available to have an effect. The study is designed to ensure the safety and well-being of participants while providing valuable information about the medication’s absorption in the body.

]]> Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis https://clinicaltrials.eu/trial/study-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-al-amyloidosis/ Wed, 29 Apr 2026 15:00:21 +0000 https://clinicaltrials.eu/trial/study-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-al-amyloidosis/ This clinical trial is focused on studying a condition known as AL amyloidosis, which is a rare disease that occurs when a protein called amyloid builds up in organs and tissues, affecting their normal function. The study is specifically looking at patients whose disease has returned after treatment or has not responded to previous treatments, referred to as “relapsed or refractory” cases. The treatment being tested in this trial is a medication called Belantamab Mafodotin, which is administered as a powder mixed into a solution for injection.

The purpose of the study is to evaluate how effective Belantamab Mafodotin is in treating patients with relapsed or refractory AL amyloidosis. Participants in the study will receive the medication through an intravenous injection, which means it is given directly into a vein. The study will monitor the participants over a period of time to see how their condition responds to the treatment. This includes checking for any changes in the disease and observing any side effects that may occur.

Throughout the study, researchers will collect data to understand the safety and effectiveness of Belantamab Mafodotin. The trial aims to provide valuable information that could lead to better treatment options for people with this challenging condition. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the course of the study.

]]> Study on the Effectiveness of Isatuximab, Pomalidomide, and Dexamethasone for Patients with AL Amyloidosis Not Responding Well to Previous Treatments https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-isatuximab-pomalidomide-and-dexamethasone-for-patients-with-al-amyloidosis-not-responding-well-to-previous-treatments/ Wed, 29 Apr 2026 14:57:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-isatuximab-pomalidomide-and-dexamethasone-for-patients-with-al-amyloidosis-not-responding-well-to-previous-treatments/ This clinical trial is focused on studying a condition known as AL Amyloidosis. This is a rare disease where abnormal proteins, called amyloids, build up in organs and tissues, affecting their normal function. The study will evaluate a combination treatment involving three medications: Isatuximab, Pomalidomide, and Dexamethasone. Isatuximab is a type of protein treatment known as a monoclonal antibody, which targets specific cells in the body. Pomalidomide is a medication that helps the immune system fight cancer, and Dexamethasone is a steroid that reduces inflammation and helps with the effectiveness of the other drugs.

The purpose of this study is to assess how well this combination of medications works in patients with AL Amyloidosis who have not achieved a very good response from previous treatments. Participants will receive the medications over a period of up to 12 months. The treatment involves taking Pomalidomide and Dexamethasone orally, while Isatuximab is given through an intravenous infusion, which means it is administered directly into a vein. The study will monitor the participants’ response to the treatment, focusing on improvements in their condition and any side effects experienced.

Throughout the study, participants will undergo regular assessments to track their health and the effectiveness of the treatment. These assessments will help determine if the combination of Isatuximab, Pomalidomide, and Dexamethasone can provide a better outcome for patients with AL Amyloidosis compared to previous therapies. The study aims to provide valuable information that could lead to improved treatment options for this challenging condition.

]]> Hematoonkologia https://clinicaltrials.eu/organisation/hematoonkologia/ Wed, 29 Apr 2026 13:34:18 +0000 https://clinicaltrials.eu/organisation/hematoonkologia/ Fundacja Hematoonkologia is a Polish non-profit organization that serves as a key source of support and information for patients with hematological cancers. The foundation offers accessible materials on diagnosis, treatment methods, symptoms, and living with hematological diseases (e.g., leukemias, lymphomas, multiple myeloma). It also helps families cope with emotional challenges. The foundation works to raise public awareness about hematological cancers.

]]>